NEW YORK (Thomson Financial) - Immunomedics Inc. said Wednesday its
milatuzumab antibody showed promising therapeutic activity for B-cell lymphoma
in animal models in preclinical studies.
Milatuzumab is a humanized anti-CD74 antibody being studied for the
treatment of multiple myeloma.
The San Francisco-based drug maker said the drug showed "significantly
improved efficacy" when combined with anti-CD20 antibodies.
The stock fell 1.5% to $2.58.
Wanfeng Zhou
wz/jw
COPYRIGHT
Copyright Thomson Financial News Limited 2007. All rights reserved.
The copying, republication or redistribution of Thomson Financial News Content,
including by framing or similar means, is expressly prohibited without the prior
written consent of Thomson Financial News.
|